Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates Read more
Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance (palbociclib) Read more
eFFECTOR Enters Into Agreement with Pfizer to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types Read more